Volume 5 Number 1 2026
Nanotheranostics for Overcoming Tumor Heterogeneity and Drug Resistance in Solid Tumors: Imaging-Guided Therapy, Clinical Progress, and Future Directions
Apura Orka 1*
Biosensors and Nanotheranostics 5 (1) 1-8 https://doi.org/10.25163/biosensors.5111004
Submitted: 19 October 2026 Revised: 10 December 2026 Accepted: 16 December 2026 Published: 18 December 2026
Solid tumors remain among the most lethal human malignancies, in large part because they are not uniform masses but evolving, heterogeneous ecosystems that resist systemically delivered drugs. Genetic, phenotypic, and microenvironmental diversity, compounded by multidrug resistance (MDR), allows subclonal populations to survive conventional therapy, while a hostile tumor microenvironment (TME)—acidic, hypoxic, fibrotic, and poorly perfused—physically blocks drug penetration and reinforces efflux-mediated resistance. Nanotheranostics, which integrates diagnostic imaging reporters and therapeutic payloads within a single nanoscale platform, has emerged as a rational response to these intertwined problems. In this review we examine how multifunctional nanotheranostic systems—lipid and polymeric carriers, inorganic and metallic hybrids, catalytic nanozymes, biomimetic cell-derived vesicles, and structural DNA architectures—are engineered to remain quiescent in circulation and switch “ON” in response to endogenous (pH, redox, hypoxia, enzymes) or exogenous (light, ultrasound, magnetic) triggers. We then consider how magnetic resonance imaging, computed tomography, positron emission tomography, ultrasound, and near-infrared optical imaging enable patient stratification, real-time tracking of drug release, and spatiotemporally controlled activation of phototherapy, radiotherapy, and immunotherapy. Preclinical and early clinical evidence, including AGuIX®, ferumoxytol, Onivyde®, and 64Cu-MM-302, indicates that imaging-guided design can reverse resistance, remodel the stroma, and identify the patients most likely to respond. We also confront the translational bottlenecks—synthetic over-engineering, the protein corona, clearance, and regulatory hurdles—that keep roughly ninety percent of candidates in animal models, and we outline how artificial intelligence, companion diagnostics, and liquid biopsy may close that gap. Read together, the evidence reframes resistance as a spatial problem of drug delivery and positions imaging-guided nanotheranostics as a practical route toward personalized oncology.
Keywords: nanotheranostics; tumor heterogeneity; multidrug resistance; tumor microenvironment; stimuli-responsive nanoparticles; image-guided therapy; companion diagnostics; clinical translation
Aghighi, M., Theruvath, A. J., Pareek, A., Pisani, L. L., Alford, R., Muehe, A. M., Sethi, T. K., Holdsworth, S. J., Hazard, F. K., Gratzinger, D., Luna-Fineman, S., Advani, R., Spunt, S. L., & Daldrup-Link, H. E. (2018). Magnetic resonance imaging of tumor-associated macrophages: Clinical translation. Clinical Cancer Research, 24(17), 4110–4118.
AGuIX. (2021a). Stereotactic radiotherapy with or without AGuIX in brain metastases (ClinicalTrials.gov Identifier: NCT04899908). U.S. National Library of Medicine.
AGuIX. (2021b). AGuIX combined with radiotherapy and temozolomide in newly diagnosed glioblastoma (NANO-GBM) (ClinicalTrials.gov Identifier: NCT04881032). U.S. National Library of Medicine.
Alberts, D. S., Muggia, F. M., Carmichael, J., Winer, E. P., Jahanzeb, M., Venook, A. P., Skubitz, K. M., Rivera, E., Sparano, J. A., & Greenspan, D. L. (2004). Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. Seminars in Oncology, 31(6 Suppl 13), 53–90.
Bareche, Y., Buisseret, L., Gruosso, T., Girard, E., Venet, D., Dupont, F., Desmedt, C., Larsimont, D., Park, M., Rothé, F., Stagg, J., & Sotiriou, C. (2020). Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: Towards an optimized treatment approach. Journal of the National Cancer Institute, 112(7), 708–719. https://doi.org/10.1093/jnci/djz208
Barros, R. B., et al. (2025). Nitroreductase-responsive gated mesoporous silica nanoparticles for controlled drug delivery under hypoxic conditions. International Journal of Pharmaceutics, 650, 123710.
Beckers, C., Pruschy, M., & Vetrugno, I. (2024). Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities. Seminars in Cancer Biology, 98, 19–30. https://doi.org/10.1016/j.semcancer.2023.11.006
Bin Emran, T., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nain, Z., Wahab, S., Rauf, A., Al-Harrasi, A., & Kim, B. (2022). Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches. Frontiers in Oncology, 12, 891652.
Bort, G., Lux, F., Dufort, S., Crémillieux, Y., Verry, C., & Tillement, O. (2020). EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles. Theranostics, 10(3), 1319–1331.
Cai, H., Wang, X. J., Zhang, H., Sun, L., Pan, D. Y., Gong, Q. Y., & Luo, K. (2018). Enzyme-sensitive biodegradable and multifunctional polymeric conjugate as theranostic nanomedicine. Applied Materials Today, 11, 207–218.
Cai, H., Xiang, Y., Zeng, Y., Li, Z., Zheng, X., Luo, Q., Zhu, H., Gong, Q., Gu, Z., Liu, Y., Zhang, H., & Luo, K. (2021). Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment. Acta Pharmaceutica Sinica B, 11(2), 544–559.
Chen, C., Yu, M., Li, Q., Zhou, Y., Zhang, M., Cai, S., & Ding, D. (2024). Programmable tetrahedral DNA-RNA nanocages woven with stimuli-responsive siRNA for enhancing therapeutic efficacy of multidrug-resistant tumors. Advanced Science, 11(20), e2404112.
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017). Rethinking cancer nanotheranostics. Nature Reviews Materials, 2(7), 17024. https://doi.org/10.1038/natrevmats.2017.24
Chen, L., Liu, M., Wang, Y., Wei, W., Li, Y., Bai, Y., Yu, X., Jiao, L., & Wang, M. (2024). TME-activated MnO2/Pt nanoplatform of hydroxyl radical and oxygen generation to synergistically promote radiotherapy and MR imaging of glioblastoma. International Journal of Nanomedicine, 19, 11055–11070. https://doi.org/10.2147/IJN.S474098
Chen, M., Wang, Y., Niu, Y., Chen, X., Su, H., Xia, L., Liu, C., Zhou, J., Wang, Z., Li, B., & Lu, D. (2026). pH-responsive CaCO3 nanoplatform amplifies SDT via calcium overload-ROS loop for deep tumor therapy. iScience, 29(3), 115082. https://doi.org/10.1016/j.isci.2026.115082
Comerford, K. M., Wallace, T. J., Karhausen, J., Louis, N. A., Montalto, M. C., & Colgan, S. P. (2002). Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Research, 62(12), 3387–3394.
Cook, A. B., & Decuzzi, P. (2021). Harnessing endogenous stimuli for responsive materials in theranostics. ACS Nano, 15(2), 2068–2098.
Dallavalle, S., Dobricic, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020). Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resistance Updates, 50, 100682.
Danhier, F. (2016). To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? Journal of Controlled Release, 244(Pt A), 108–121. https://doi.org/10.1016/j.jconrel.2016.11.015
de Maar, J. S., Sofias, A. M., Vila, R., Storm, G., Kiessling, F., Moonen, C., & Lammers, T. (2020). Imaging spatial therapy heterogeneity in cancer. Theranostics, 10(4), 1884–1904.
Dhandapani, R., Ramasamy, T., Shanmugam, S., & Choi, H. G. (2023). Self-assembled multifunctional nanotheranostics against circulating tumor clusters in metastatic breast cancer. Acta Pharmaceutica Sinica B, 13(4), 1711–1726.
Dhas, N., García, M. C., Kudarha, R., Pandey, A., Nikam, A. N., Gopalan, D., & Mutalik, S. (2022). Advancements in cell membrane camouflaged nanoparticles: A bioinspired platform for cancer therapy. Journal of Controlled Release, 346, 71–97.
Ehlerding, E. B., Grodzinski, P., Cai, W., & Liu, C. H. (2018). Big potential from small agents: Nanoparticles for imaging-based companion diagnostics. ACS Nano, 12(3), 2106–2121.
Fang, R. H., Kroll, A. V., Gao, W. W., & Zhang, L. F. (2018). Cell membrane coating nanotechnology. Advanced Materials, 30(23), e1706759.
Feng, L., Dong, Z., Tao, D., Zhang, Y., & Liu, Z. (2018). The acidic tumor microenvironment: A target for smart cancer nano-theranostics. National Science Review, 5(2), 269–286.
Fiori, M. E., Di Franco, S., Villanova, L., Bianca, P., Stassi, G., & De Maria, R. (2019). Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Molecular Cancer, 18(1), 70.
Gawne, P. J., Ferreira, M., Papaluca, M., Grimm, J., & Decuzzi, P. (2023). New opportunities and old challenges in the clinical translation of nanotheranostics. Nature Reviews Materials, 8(12), 783–798. https://doi.org/10.1038/s41578-023-00581-x
Gebhart, G., Lamberts, L. E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M., Aftimos, P., Tol, J., Oyen, W. J. G., Vugts, D. J., Hoekstra, O. S., Schröder, C. P., Menke-van der Houven van Oordt, C. W., Guiot, T., Brouwers, A. H., Awada, A., de Vries, E. G. E., & Flamen, P. (2016). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial. Annals of Oncology, 27(4), 619–624.
Horvat, N. K., Chocarro, S., Marques, O., Bauer, T. A., Qiu, R., Diaz-Jimenez, A., Helm, B., Chen, Y., Sawall, S., Sparla, R., & Daldrup-Link, H. E. (2024). Superparamagnetic iron oxide nanoparticles reprogram the tumor microenvironment and reduce lung cancer regrowth after crizotinib treatment. ACS Nano, 18(16), 11025–11041. https://doi.org/10.1021/acsnano.3c08335
Jain, R. K. (2005). Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science, 307(5706), 58–62.
Juku, I. I., Xing, L., Li, Y., Wei, F., Zhu, M., Li, X., Deng, X., Xu, F., Deng, S., & Jia, Y. (2026). Peptide-guided nanotheranostics engaging the tumor fibrin-fibronectin niche: From CREKA to clinical translation. TransMed, 100064. https://doi.org/10.1016/j.tmed.2026.100064
Khan, M. Y., Chen, J.-K., Jain, V., Agrawal, L., Lin, C.-A. J., & Chen, M.-H. (2024). The influence of surface modification on the shortwave infrared emission of rare-earth-doped nanoparticles. Journal of Medical and Biological Engineering, 44(1), 49–56.
Khan, M. Y., Muheyuddeen, G., Niranjan, A. K., Pandey, M., Jabi, B., Singh, A., & Chen, M.-H. (2026). Microneedle-delivered hybrid carbon–lanthanide nanotheranostic platform for precision localized therapy of early-stage melanoma. Next Nanotechnology, 9, 100540.
Kievit, F. M., & Zhang, M. (2011). Cancer nanotheranostics: Improving imaging and therapy by targeted delivery across biological barriers. Advanced Materials, 23(36), H217–H247.
Kothawade, S., Bhange, M., & Pande, V. V. (2025). Advanced nanotheranostic approaches for hepatocellular carcinoma management. Journal of Medicine, Surgery, and Public Health, 6, 100188.
Large, D. E., Abdelmessih, R. G., Fink, E. A., & Auguste, D. T. (2021). Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Advanced Drug Delivery Reviews, 176, 113851.
Lee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I., Ma, C. X., LoRusso, P. M., Munster, P. N., Campbell, K., Gaddy, D. F., Leonard, S. C., Geretti, E., Blocker, S. J., Kirpotin, D. B., Moyo, V., Wickham, T. J., & Hendriks, B. S. (2017). 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clinical Cancer Research, 23(15), 4190–4202.
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S. B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008). Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 108(2), 241–250.
Li, J., Wu, M., Guo, Q., Gong, Y., Gao, Z., Zhao, Y., Zhang, X., & Li, X. (2026). Visualized liposomal platforms remodel the tumor immunosuppressive and hypoxic microenvironment to potentiate radiotherapy in hepatocellular carcinoma. Materials Today Advances, 30, 100803.
Li, J., Zeng, L., Wang, Z., Chen, H., Fang, S., Wang, J., & Chao, H. (2022). Cycloruthenated self-assembly with metabolic inhibition to efficiently overcome multidrug resistance in cancers. Advanced Materials, 34(15), e2100245.
Li, Y., Wu, Q., Li, D., Huang, J., Wen, H., Wu, Y., & Tang, B. Z. (2021). A nanotheranostic system combining lysosomal cell death and nuclear apoptosis functions for synergistic cancer therapy and addressing drug resistance. Advanced Functional Materials, 31(48), 2106091.
Liu, R., Jiang, W., Walkey, C. D., Chan, W. C. W., & Cohen, Y. (2015). Prediction of nanoparticles–cell association based on corona proteins and physicochemical properties. Nanoscale, 7(21), 9664–9675.
Luther, D. C., Huang, R., Jeon, T., Zhang, X. Z., Lee, Y. W., Nagaraj, H., & Rotello, V. M. (2020). Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. Advanced Drug Delivery Reviews, 156, 188–213.
Ma, Z., Jia, X., Bai, J., Ruan, Y., Wang, C., Li, J., Zhang, M., & Jiang, X. (2017). MnO2 gatekeeper: An intelligent and O2-evolving shell for preventing premature release of high cargo payload core, overcoming tumor hypoxia, and acidic H2O2-sensitive MRI. Advanced Functional Materials, 27(4), 1604258. https://doi.org/10.1002/adfm.201604258
Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research, 46(12 Pt 1), 6387–6392.
Melancon, M. P., Stafford, R. J., & Li, C. (2012). Challenges to effective cancer nanotheranostics. Journal of Controlled Release, 164(2), 177–182.
Mendes, B. B., Sousa, D. P., Conniot, J., & Conde, J. (2021). Nanomedicine-based strategies to target and modulate the tumor microenvironment. Trends in Cancer, 7(9), 847–862. https://doi.org/10.1016/j.trecan.2021.05.001
Mi, P., Kokuryo, D., Cabral, H., Wu, H., Terada, Y., Saga, T., Aoki, I., Nishiyama, N., & Kataoka, K. (2016). A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy. Nature Nanotechnology, 11(8), 724–730.
Miller, M. A., Arlauckas, S., & Weissleder, R. (2017). Prediction of anti-cancer nanotherapy efficacy by imaging. Nanotheranostics, 1(3), 296–312.
Molina-Garcia, D., Garcia-Vicente, A. M., Perez-Beteta, J., Amo-Salas, M., Martinez-Gonzalez, A., Tello-Galan, M. J., & Perez-Garcia, V. M. (2018). Intratumoral heterogeneity in 18F-FDG PET/CT by textural analysis in breast cancer as a predictive and prognostic subrogate. Annals of Nuclear Medicine, 32(6), 379–388.
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015). New developments in liposomal drug delivery. Chemical Reviews, 115(19), 10938–10966.
Pei, Z. F., Lei, H. L., & Cheng, L. (2023). Bioactive inorganic nanomaterials for cancer theranostics. Chemical Society Reviews, 52(6), 2031–2081.
Pillarisetti, S., et al. (2026). Oxidative cues as theranostic switches for ROS-responsive nanotheranostics in oxidative stress-driven diseases. Journal of Controlled Release, 394, 114933.
Prasad, R., Mendes, B. B., Gorain, M., Kundu, G. C., Gupta, N., Peng, B., Win, E. H. A., Qing, H., & Conde, J. (2023). Bioinspired and biomimetic cancer-cell-derived membrane nanovesicles for preclinical tumor-targeted nanotheranostics. Cell Reports Physical Science, 4(11), 101648. https://doi.org/10.1016/j.xcrp.2023.101648
Qi, Y., Yan, X., Xia, T., & Liu, S. (2021). Use of macrophage as a Trojan horse for cancer nanotheranostics. Materials & Design, 198, 109388. https://doi.org/10.1016/j.matdes.2020.109388
Raghunand, N., & Gillies, R. J. (2000). pH and drug resistance in tumors. Drug Resistance Updates, 3(1), 39–47.
Ren, F., Wang, F., Baghdasaryan, A., Li, Y., Liu, H., Hsu, R., Wang, C., Li, J., Zhong, Y., Salazar, F., Xu, C., Jiang, Y., Ma, Z., Zhu, G., Zhao, X., Wong, K. K., Willis, R., Garcia, K. C., Wu, A., Mellins, E., & Dai, H. (2024). Shortwave-infrared-light-emitting probes for the in vivo tracking of cancer vaccines and the elicited immune responses. Nature Biomedical Engineering, 8(6), 726–739.
Sajid, A., Rahman, H., & Ambudkar, S. V. (2023). Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nature Reviews Cancer, 23(11), 762–779.
Salvati, A., Aberg, C., dos Santos, T., Varela, J., Pinto, P., Lynch, I., & Dawson, K. A. (2013). Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nature Nanotechnology, 8(2), 137–143.
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., & Chan, W. C. W. (2020). The entry of nanoparticles into solid tumours. Nature Materials, 19(5), 566–575.
Stapleton, S., Milosevic, M., Tannock, I. F., Allen, C., & Jaffray, D. A. (2015). The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation. Journal of Controlled Release, 211, 163–170.
Theek, B., Gremse, F., Kunjachan, S., Fokong, S., Pola, R., Pechar, M., Deckers, R., Storm, G., Ehling, J., Kiessling, F., & Lammers, T. (2014). Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. Journal of Controlled Release, 182, 83–89.
Tian, Y., Wang, P., Li, X., Zhang, Y., & Chen, H. (2025). Nano-drug delivery systems targeting tumor microenvironment to overcome multidrug resistance: A review. Theranostics, 15(4), 1689–1723.
Todd, D. J., & Kay, J. (2016). Gadolinium-induced fibrosis. Annual Review of Medicine, 67, 273–291.
Verry, C., Dufort, S., Villa, J., Gavard, M., Iriart, C., Grand, S., Charles, J., Chovelon, B., Cracowski, J. L., Quesada, J. L., & Tillement, O. (2021). Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Radiotherapy and Oncology, 160, 159–165. https://doi.org/10.1016/j.radonc.2021.04.021
Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., LoRusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Vasquez, D. M., & Zale, S. E. (2016). Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clinical Cancer Research, 22(13), 3157–3163.
Wang, D., Yi, H., Geng, S., Jiang, C., Liu, J., Duan, J., & Wang, L. (2023). Photoactivated DNA nanodrugs damage mitochondria to improve gene therapy for reversing chemoresistance. ACS Nano, 17(17), 16923–16934.
Wang, K., Lu, X., Wang, S., & Zhang, Q. (2026). Activatable MRI nanoprobes for tumor and immune microenvironment imaging: Biological mechanisms and translational implications. Materials Today Bio, 41, 103717. https://doi.org/10.1016/j.mtbio.2026.103717
Wang-Gillam, A., Li, C. P., Bodoky, G., Dean, A., Shan, Y. S., Jameson, G., Macarulla, T., Lee, K. H., Cunningham, D., Blanc, J. F., Chung, V. D., de Groot, L., Chen, L. T., & NAPOLI-1 Study Group. (2016). Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. The Lancet, 387(10018), 545–557.
Wei, D., Sun, Y., Zhu, H., & Fu, Q. (2023). Stimuli-responsive polymer-based nanosystems for cancer theranostics. ACS Nano, 17(23), 23223–23261.
Wike-Hooley, J. L., Haveman, J., & Reinhold, H. S. (1984). The relevance of tumour pH to the treatment of malignant disease. Radiotherapy and Oncology, 2(4), 343–366.
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016). Analysis of nanoparticle delivery to tumors. Nature Reviews Materials, 1(5), 16014. https://doi.org/10.1038/natrevmats.2016.14
Wu, X., Liang, J., Shu, J., Li, Z., Yin, T., Zhang, X., & Chao, H. (2025). Narrow-bandgap Iridium(III)-C3N5 nanocomplex as an oxygen self-sufficient piezo-sonosensitizer for hypoxic tumor sonodynamic immunotherapy. Journal of the American Chemical Society, 147(18), 15329–15343.
Wu, X., Wu, Y., et al. (2026). Acoustic-magnetic nanoplatforms for spatiotemporally coordinated tumor diagnosis and therapy. Bioactive Materials, 45, 1–32.
Yang, C., Pang, X., Chen, W., Wang, X., Lin, G., Chu, C., Zhang, X., Deng, X., Chen, X., & Liu, G. (2019). Environmentally responsive dual-targeting nanotheranostics for overcoming cancer multidrug resistance. Science Bulletin, 64(10), 705–714. https://doi.org/10.1016/j.scib.2019.04.019
Yang, H., Qu, Y., Tian, Y., Wang, C., Sun, Y., Dai, Z., Yue, X., & Cheng, W. (2024). Ultrasound-targeted microbubble destruction enhances the inhibitory effect of sonodynamic therapy against hepatocellular carcinoma. ACS Omega, 9(52), 51253–51263.
Yoon, H. J., Kim, Y., Chung, J., & Kim, B. S. (2019). Predicting neo-adjuvant chemotherapy response and progression-free survival of locally advanced breast cancer using textural features of intratumoral heterogeneity on F-18 FDG PET/CT and diffusion-weighted MR imaging. The Breast Journal, 25(3), 373–380.
Yoon, S. H., Kim, Y. H., Lee, Y. J., Park, J., Kim, J. W., Lee, H. S., & Lee, K. W. (2016). Tumor heterogeneity in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer assessed by CT texture analysis: Association with survival after trastuzumab treatment. PLOS ONE, 11(8), e0161278.
Yuan, Z., Zhang, Y., Cao, D., Shen, K., Li, Q., Zhang, G., & Xiang, Y. (2021). Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer. Journal of Ovarian Research, 14(1), 12.
Zachou, M.-E., Spyratou, E., Lagopati, N., Platoni, K., & Efstathopoulos, E. P. (2025). Recent progress of nanomedicine for the synergetic treatment of radiotherapy (RT) and photothermal treatment (PTT). Cancers, 17(14), 2295.
Zhang, Y., Fang, Z., Pan, D., Li, Y., Zhou, J., & Chen, H. (2024). Dendritic polymer-based nanomedicines remodel the tumor stroma: Improve drug penetration and enhance antitumor immune response. Advanced Materials, 36(24), 2401304.
Zhang, Y., Zhang, T., Cui, C., Wang, W., Sun, J., & Liu, Y. (2025). Curcumin-loaded nanotheranostics for cancer therapy: Advances in biosensing, imaging, and multimodal therapy. Industrial Crops & Products, 235, 121518. https://doi.org/10.1016/j.indcrop.2025.121518
Zheng, F., Su, Y., Sun, X., Tan, D., Wang, Y., Li, X., & Gao, Y. (2026). Chitosan-based nanotheranostics integrated dual-modal imaging and combinatorial tumor therapy for EGFR-TKI resistance reversal. Materials Today Bio, 39, 103420.
Zhi, S., Zhang, X., Zhang, J., Wang, X. Y., & Bi, S. (2023). Functional nucleic acids-engineered bio-barcode nanoplatforms for targeted synergistic therapy of multidrug-resistant cancer. ACS Nano, 17(14), 13533–13544.
Targeted Protein Degraders (PROTACs) Overcome KRAS Inhibitor Resistance and Remodel Antitumor Immunity in Lung Cancer
Sustainable and Green Nanomaterials in Biosensing and Nanotheranostics: Life-Cycle, Toxicity, and Circular Design Perspectives
Nanoparticle-Mediated Ferroptosis Induction Combined with MRI Monitoring in Therapy-Resistant Cancers